Semax: A Research Overview of the Neuroprotective Peptide
With hundreds of published studies and a track record in clinical research, Semax is one of the most scientifically documented peptides in existence. Here's what Canadian researchers need to know.
One of the Most Studied Neuroprotective Peptides Ever Developed
If research volume is any indication of scientific interest, Semax has earned its reputation.
Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of hundreds of peer-reviewed studies spanning over three decades. It has been investigated in clinical settings in Russia and Eastern Europe, and has been the focus of growing research interest internationally.
For Canadian researchers studying cognitive aging, neuroprotection, and BDNF-related pathways, Semax represents one of the best-documented peptides available.
What Is Semax?
Semax is derived from the N-terminal fragment of ACTH (adrenocorticotropic hormone) — specifically the 4-7 amino acid sequence of ACTH(4-7), extended with a Pro-Gly-Pro sequence that enhances stability and biological activity.
The modification was intentional: researchers wanted to retain the cognitive effects associated with ACTH fragments while improving resistance to enzymatic breakdown. The result is a compound with a more favorable research profile than native ACTH fragments.
BDNF: The Primary Research Focus
Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that promotes neuronal survival, synaptic plasticity, and the formation of new neural connections. Reduced BDNF expression has been associated in research models with cognitive decline, depression, and neurodegenerative conditions.
Semax has been shown in multiple preclinical studies to upregulate BDNF and its receptor TrkB in several brain regions, including the hippocampus — a structure critical to memory formation and consolidation.
This BDNF-upregulating property is one of the most replicated findings in the Semax literature and represents the primary mechanism through which its cognitive effects are theorized to occur.
Neuroprotection Under Ischemic Conditions
One of the most studied applications of Semax in the published literature involves neuroprotection under ischemic conditions. Multiple studies have investigated whether Semax can reduce neuronal damage following experimental stroke models in rodents.
The proposed mechanisms include reduction of pro-inflammatory cytokine expression, modulation of nitric oxide synthesis, and enhancement of antioxidant enzyme activity in neuronal tissue. This area of research has produced some of the most clinically relevant findings in the Semax literature.
Cognitive and Attention Effects
Beyond neuroprotection, Semax has been studied for its effects on attention, working memory, and processing speed in preclinical models. Research has also examined its potential interactions with the dopaminergic and serotonergic systems, which may contribute to its cognitive profile.
The compound has been investigated in human subjects in Russia for stroke recovery, optic nerve atrophy, and attention deficit conditions — giving it an unusually extensive research record compared to most peptides in this category.
The Intranasal Research Route
Semax is almost exclusively administered intranasally in both preclinical and clinical research. This is not incidental — the nasal route provides direct access to the CNS via the olfactory pathway, and the published pharmacokinetic data for Semax is built around this delivery route.
For Canadian researchers who want to replicate or extend findings from the existing literature, the nasal spray format is the most scientifically aligned choice.
Popular Peptides Semax Nasal Spray
Popular Peptides supplies Semax Nasal Spray (10ml) as a research-grade compound for Canadian investigators. ≥99% purity, independently third-party tested, Certificate of Analysis included.
**Disclaimer**: For laboratory and research use only. Not approved by Health Canada for therapeutic use.